Response to article – alternative interpretation of “there is reduced immunohistochemical staining of placental aromatase in severe neonatal opioid withdrawal syndrome”

Julia TobacykDepartment of Pharmacology and Toxicology, College of Medicine, University of Arkansas for Medical Sciences, Little Rock, AR, USAView further author information

Lisa K. BrentsDepartment of Pharmacology and Toxicology, College of Medicine, University of Arkansas for Medical Sciences, Little Rock, AR, USACorrespondence[email protected]
View further author information

References

Townsel C, Odukoya E, Rae J, et al. There is reduced immunohistochemical staining of placental aromatase in severe neonatal opioid withdrawal syndrome. J Matern Fetal Neonatal Med. 2022;2:1–7.
Google Scholar
Nanovskaya TN, Deshmukh SV, Nekhayeva IA, et al. Methadone metabolism by human placenta. Biochem Pharmacol. 2004;68(3):583–591.
PubMed Web of Science ®Google Scholar
Deshmukh SV, Nanovskaya TN, Ahmed MS. Aromatase is the major enzyme metabolizing buprenorphine in human placenta. J Pharmacol Exp Ther. 2003;306(3):1099–1105.
PubMed Web of Science ®Google Scholar
Jones HE, Kaltenbach K, Heil SH, et al. Neonatal abstinence syndrome after methadone or buprenorphine exposure. N Engl J Med. 2010;363(24):2320–2331.
PubMed Web of Science ®Google Scholar
Zharikova OL, Deshmukh SV, Nanovskaya TN, et al. The effect of methadone and buprenorphine on human placental aromatase. Biochem Pharmacol. 2006;71(8):1255–1264.
PubMed Web of Science ®Google Scholar